Methods for Inhibiting the Development, Formation and/or Maturation of Bacterial and Fungal Biofilms
The present disclosure describes compositions and methods for inhibiting the development, formation and/or maturation of bacterial and fungal biofilms. The biofilm inhibiting compositions include non-steroidal anti-inflammatory drugs (NSAIDs) as APIs, and ethoxylated oil as a solubilizing agent. The ethoxylated oils employed within the biofilm inhibiting compositions includes between 9 and 24 ethoxylations/molecules. The NSAIDs agents within the biofilm inhibiting compositions inhibit the syntheses of prostaglandins by blocking the cyclooxygenase (COX) enzyme system due to the analgesic, anti-inflammatory, and antipyretic properties of the NSAIDs. The biofilm inhibiting compositions inhibit the cyclooxygenase isoenzymes required for prostaglandin formation, thereby preventing the colonization of fungi or bacteria as well as the formation of biofilms.
1 . A method of inhibiting a biofilm comprising applying a topical pharmaceutical composition including at least one non-steroidal anti-inflammatory drug (NSAID) and at least one solubilizing agent to a body surface of a patient.
2 . The method of inhibiting a biofilm of claim 1 , wherein the at least one NSAID comprises at least one selected from the group consisting of acetylsalicylic acid, bucloxic acid, flufenamic acid, mefanamic acid, niflumic acid, tiaprofenic acid, tolfenamic acid, bendazac, carprofen, ketoprofen, diclofenac, diflunisal, etodolac, fenbufen, fenoprofen, fentiazac, flurbiprofen, isoxicam, naproxen, pirfrofen, piroxicam, sulindac, suprofen, tenoxicam, tolmetin, and zomepirac.
3 . The method of inhibiting a biofilm of claim 1 , wherein the at least one solubilizing agent comprises at least one ethoxylated oil.
4 . The method of inhibiting a biofilm of claim 4 , wherein the at least one ethoxylated oil includes a PEGylated oil including 9 to 24 ethoxylations.
5 . The method of inhibiting a biofilm of claim 1 , wherein the topical pharmaceutical composition comprises about 0.1% w/w to about 5% w/w of the at least one NSAID.
6 . The method of inhibiting a biofilm of claim 3 , wherein the topical pharmaceutical composition comprises about 1% w/w to about 20% w/w of the at least one ethoxylated oil.
7 . The method of inhibiting a biofilm of claim 5 , wherein the at least one solubilizing agent includes at least one ethoxylated oil and wherein the topical pharmaceutical composition comprises about 1% w/w to about 20% w/w of the at least one ethoxylated oil.
8 . The method of inhibiting a biofilm of claim 5 , wherein the topical pharmaceutical composition comprises about 2% w/w to about 5% w/w of the at least one NSAID.
9 . The method of inhibiting a biofilm of claim 7 , wherein the topical pharmaceutical composition comprises about 2% w/w to about 5% w/w of the at least one NSAID.
10 . The method of inhibiting a biofilm of claim 6 , wherein the topical pharmaceutical composition comprises about 5% w/w to about 10% w/w of the at least one ethoxylated oil.
11 . The method of inhibiting a biofilm of claim 7 , wherein the topical pharmaceutical composition comprises about 5% w/w to about 10% w/w of the at least one ethoxylated oil.
12 . The method of inhibiting a biofilm of claim 9 , wherein the topical pharmaceutical composition comprises about 5% w/w to about 10% w/w of the at least one ethoxylated oil.
13 . The method of inhibiting a biofilm of claim 7 , wherein the topical pharmaceutical composition is selected from the group consisting of an ointment, a cream, a gel, a lotion, a solution, and a paste.
14 . The method of inhibiting a biofilm of claim 7 , wherein about 500 mg/day to about 5000 mg/day of the topical pharmaceutical composition is applied to the body surface of the patient.
15 . The method of inhibiting a biofilm of claim 14 , wherein about 1000 mg/day to about 3000 mg/day of the topical pharmaceutical composition is applied to the body surface of the patient.
16 . The method of inhibiting a biofilm of claim 12 , wherein about 500 mg/day to about 5000 mg/day of the topical pharmaceutical composition is applied to the body surface of the patient.
17 . The method of inhibiting a biofilm of claim 16 , wherein about 1000 mg/day to about 3000 mg/day of the topical pharmaceutical composition is applied to the body surface of the patient.
18 . A topical pharmaceutical composition comprising about 0.1% w/w to about 5% w/w of at least one non-steroidal anti-inflammatory drug (NSAID) including at least one selected from the group consisting of acetylsalicylic acid, bucloxic acid, flufenamic acid, mefanamic acid, niflumic acid, tiaprofenic acid, tolfenamic acid, bendazac, carprofen, ketoprofen, diclofenac, diflunisal, etodolac, fenbufen, fenoprofen, fentiazac, flurbiprofen, isoxicam, naproxen, pirfrofen, piroxicam, sulindac, suprofen, tenoxicam, tolmetin, and zomepirac and about 1% w/w to about 20% w/w of ethoxylated oils.
19 . The topical pharmaceutical composition of claim 18 comprising about 2% w/w to about 5% w/w of the at least one non-steroidal anti-inflammatory drug (NSAID) and about 5% w/w to about 10% w/w of the ethoxylated oils.
20 . The topical pharmaceutical composition of claim 19 , wherein the ethoxylated oils are PEGylated oils including 9 to 24 ethoxylations.